Claims for Patent: RE39155

Summary for Patent: RE39155

Title:	Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B
Abstract:	Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed. ##STR00001##
Inventor(s):	Belleau; Pierrette (Montreal, CA), Nguyen-Ba; Nghe (La Praire, CA), Belleau; Bernard (Westmont, CA)
Assignee:	Shire BioChem Inc. (Quebec, CA)
Application Number:	09/585,431
Patent Claims:	1. A method for the treatment of .Iadd.hepatitis B infection, in .Iaddend.a mammal, including a human, suffering from hepatitis B infection, comprising administration of an effective amount of a compound of formula (I) ##STR00005## or a pharmaceutically acceptable salt, ester, or salt of an ester thereof to said mammal. 2. The method according to claim 1 wherein the hepatitis B infection is human hepatitis B. 3. The method according to claim 1 wherein the compound of formula (I) comprises (.+-.)-cis-4-amino-1-( 2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt, ester, or salt of an ester thereof. 4. The method according to claim 1 wherein the compound of formula (I) comprises (-)-cis-4-amino-1-( 2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt, ester, or salt of an ester thereof. 5. The method according to claim 4 wherein the compound of formula (I) is substantially free of the corresponding (+)-enantiomer. 6. The method according to any one of claims 1 to 5 wherein the compound of formula (I) is adapted for oral administration. 7. The method according to any one of claims 1 to 5 wherein the compound of formula (I) is adapted for parenteral administration. 8. The method according to any one of claims 1 to 5 wherein the compound of formula (I) is in unit dosage form. 9. The method according to claim 8 wherein the compound is present in an amount of from 10 to 1500 mg. .Iadd.10. A method for the treatment of hepatitis B infection, in a human, suffering from hepatitis B infection, comprising administering to said human an effective amount of a compound of formula (I) ##STR00006## or a pharmaceutically acceptable salt, ester, or salt of an ester thereof. .Iaddend. .Iadd.11. The method according to claim 10, wherein the compound of formula (I) is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one or a pharmaceutically acceptable salt, ester or salt of an ester thereof. .Iaddend. .Iadd.12. A method for the treatment of hepatitis B infection, in a human, suffering from hepatitis B infection, comprising administering to said human an effective amount of a compound of formula (I) ##STR00007## or a pharmaceutically acceptable salt thereof. .Iaddend. .Iadd.13. The method according to claim 12, wherein the compound of formula (I) is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one or a pharmaceutically acceptable salt thereof. .Iaddend. .Iadd.14. The method according to claim 10, comprising administering a compound of formula (I). .Iaddend. .Iadd.15. The method according to claim 13, comprising administering (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one. .Iaddend. .Iadd.16. The method according to claim 11, wherein the (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one or pharmaceutically acceptable salt thereof is substantially free of the corresponding (+)-enantiomer. .Iaddend. .Iadd.17. The method according to claim 13, wherein the (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one or pharmaceutically acceptable salt thereof is substantially free of the corresponding (+)-enantiomer. .Iaddend. .Iadd.18. The method according to claim 15, wherein the (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one is substantially free of the corresponding (+)-enantiomer. .Iaddend.